Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 11/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | MTTP | P55157 | 11/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | APOB | P04114 | 7/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6503326 | 0.92 | SMO (0.54) | SMOTP53MTTPLMNAAPOB | |
| SCHEMBL6501350 | 0.91 | NPC1 (0.46) | SMOTP53MTTPLMNAAPOB | |
| SCHEMBL6493131 | 0.90 | TP53 (0.57) | SMOTP53MTTPLMNAAPOB | |
| SCHEMBL6792997 | 0.86 | TP53 (0.49) | SMOTP53MTTPLMNAAPOB | |
| SCHEMBL6499252 | 0.83 | POLB (0.47) | TP53MTTPLMNAAPOB | |
| SCHEMBL6492802 | 0.83 | POLB (0.47) | TP53LMNA | |
| SCHEMBL6491901 | 0.83 | MTTP (0.64) | SMOMTTPAPOB | |
| SCHEMBL6500792 | 0.83 | NPC1 (0.52) | SMOTP53MTTPLMNAAPOB | |
| SCHEMBL6495706 | 0.82 | TP53 (0.58) | SMOTP53LMNA | |
| SCHEMBL6794470 | 0.79 | TP53 (0.54) | SMOTP53MTTPLMNAAPOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | SMO 2580/4885TP53 3031/4885MTTP 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.